Exclusive Summary

• Silibinin meglumine tablets address significant global unmet medical needs as an adjunctive treatment for Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Liver Disease (ALD).
• With clear hepatoprotective effects and good safety profiles, the product holds a favorable position in pharmacopoeias and clinical guidelines across multiple countries, facilitating market access.
• Compared to originator silymarin products, silibinin meglumine tablets offer potential differentiation through improved bioavailability, leading to better patient compliance.
• As a generic drug, the product will possess significant price competitiveness in bulk procurement and reimbursement systems, aiding rapid market share capture.
• Pursuing international certifications and collaborating with experienced overseas pharmaceutical companies can leverage their established market presence and distribution networks in liver disease, accelerating global commercialization.